There is evidence of a global increase in N 2 O use among young people, along with a low level of awareness about the risks of prolonged/heavy use and late presentation to treatment after experiencing side effects. We advocate a combined effort of legislation and better education about side effects to limit problems associated with excessive N 2 O use.Nitrous oxide (N 2 O; laughing gas) has been inhaled by hundreds of millions of patients in medical settings for acute pain control mainly in surgery and dentistry since 1844. N 2 O also has a long history of recreational use, but recently, there has been an increase in recreational N 2 O use in many countries, including Australia, United Kingdom, United States, the Netherlands, and China [1-3]. The highest rate of last year N 2 O use was found in the United Kingdom in 2019/2020 with 8.7% of youngsters age 16 to 24 years [4] using N 2 O in the past year, although it has stabilized over the past few years. In the United Kingdom, N 2 O use is the second most popular drug among 16-to 24-year-olds, following cannabis [5]. In Australia, an increase of 8% in 2003 to 67% in 2020 was reported among recreational drug users in New South Wales [6]. The apparent upsurge of N 2 O use and the related public nuisance (empty balloons, canisters and bulbs) have led to an increased coverage in the media demanding legislative measures aiming to take N 2 O out of legal circulation in some countries [7], although some experts are warning that criminal drug runners will then control the market and young minors will be exposed to a myriad of more harmful controlled drugs. They propose instead that youngsters should be approached with credible information to limit their use, raise awareness of early symptoms (persistent numbness and tingling in feet, mouth, tongue and fingers) and seek help [8].Although general prevalence data are lacking for most countries and N 2 O use is usually not included in general population surveys, there are some indications that problematic N 2 O use is on the rise [1,2,9]. In the United States, the number of N 2 O related cases reported to the Food and Drug Administration (FDA) (FDA Adverse Event Reporting [FAERS] data) increased from 25 in 2012 to 2015 to 99 in 2016 to 2019 [10], which referred in 70% of cases to subjects age 13 to 29 years. The FAERS cases (n = 128) comprised hospitalization (34%), disabling events (7%), life threatening events (7%) and fatalities (25%). Improved registration of the N 2 O-related events (e.g. coding) may partly explain the increasing trends in N 2 O related adverse events, but several studies from other countries have shown a similar gradual increase in clinical cases [2,9,11,12].